Terazosin

Terazosin is a quinazoline-derived, selective antagonist at the alpha-1 adrenergic receptor, with the molecular formula C19H25N5O4. It belongs to the same drug family as prazosin and doxazosin, the group commonly called alpha-blockers, and was patented in 1975 before entering medical use in the mid-1980s. It is taken by mouth, has a long enough duration of action for once-daily dosing, and is now sold as an inexpensive generic.

The drug has two established uses. It is most often prescribed to ease the lower urinary tract symptoms of benign prostatic hyperplasia, an enlarged prostate, where relaxing muscle in the prostate and bladder neck improves urine flow and reduces straining and frequency; a randomized crossover study in men who had both hypertension and prostatic enlargement found that terazosin combined with enalapril improved symptom scores, urine flow, and residual bladder volume comparably to the beta-blocker carvedilol ^[4]. It is also used, though considered a less preferred option, to treat high blood pressure, since the same receptor blockade widens arteries. Because prostate cancer can cause similar urinary symptoms, that diagnosis is generally excluded before treatment.

Terazosin has attracted attention for an action unrelated to adrenergic receptors. Laboratory work showed that it binds the glycolytic enzyme phosphoglycerate kinase 1 (PGK1) and can raise its activity, boosting glycolysis and cellular ATP; because failing energy metabolism is a feature of Parkinson's disease, researchers tested the drug in disease models. Across toxin-induced and genetic models in mice, rats, flies, and human stem-cell-derived neurons, terazosin raised brain ATP, slowed neuron loss, increased dopamine, and partly restored movement, and analyses of large patient databases suggested slower progression and fewer diagnoses among people already taking the drug ^[1]. The relationship is intricate; a later kinetic model proposed that terazosin behaves as a competitive inhibitor that nonetheless speeds product release at low concentrations, giving a biphasic effect on the enzyme ^[2], and reviews now discuss glycolysis-enhancing agents as an experimental strategy in neurodegeneration ^[3].

As a widely available generic, terazosin remains in routine clinical use for prostatic symptoms and, in some patients, blood pressure. Its main cautions relate to blood-pressure lowering: a pronounced fall after the first dose, sometimes called the first-dose phenomenon, along with orthostatic hypotension, dizziness, and fatigue. Priapism is a rare but serious effect. Its neurodegeneration research remains investigational and is not an approved use.

Terazosin is prescription only. The best known risk is first dose hypotension, a sudden drop in blood pressure on standing that can cause dizziness or fainting, so the first dose is small and taken at bedtime. Ongoing effects include lightheadedness, tiredness, stuffy nose, swelling in the ankles and, rarely, a prolonged painful erection. Patients heading for cataract surgery should tell their eye surgeon because alpha blockers can cause intraoperative floppy iris syndrome. Combining it with erectile dysfunction drugs such as sildenafil or with other blood pressure medicines can stack the hypotensive effect.

Terazosin is an alpha-1 blocker, so the interactions that matter are those adding to vasodilation and to its first-dose orthostatic effect.

The best-characterised is with verapamil. In a controlled study of hypertensive patients, adding either drug to the other increased terazosin bioavailability and produced symptomatic orthostatic hypotension in six of twenty-four patients on the first combined dose; the effect attenuated after about three weeks of continued treatment. The investigators attributed it to combined vasodilation rather than to any negative inotropic contribution.

PDE5 inhibitors add to the same effect and can cause syncope, particularly around dose changes. Diuretics, nitrates, other antihypertensives and alcohol all deepen the fall in blood pressure. NSAIDs work the other way, blunting the antihypertensive response through sodium retention. Terazosin also causes intraoperative floppy iris syndrome during cataract surgery, which is a surgical-planning matter rather than a drug interaction.

Checking a whole stack? Run it through interactions + stacks.

Terazosin was developed by Abbott Laboratories and introduced in the late 1980s, gaining US FDA approval in 1987 under the brand name Hytrin. A quinazoline-derived selective alpha-1 adrenergic antagonist, it was designed as a longer-acting relative of prazosin, allowing convenient once-daily dosing, and was first marketed for high blood pressure before its usefulness for the urinary symptoms of benign prostatic hyperplasia became a major indication. It has been available generically for decades and is a long-established, low-cost drug.

In a striking modern development, researchers in the 2010s discovered that terazosin has a second, entirely unrelated action: it binds and stimulates the glycolytic enzyme phosphoglycerate kinase 1, boosting cellular energy production. That finding, advanced notably by groups at the University of Iowa, prompted cell, animal, and epidemiological studies suggesting the drug might slow neurodegeneration, and it has since become the focus of active research in Parkinson's disease.

Terazosin holds a solid reputation as a dependable, inexpensive workhorse for both hypertension and the urinary symptoms of an enlarged prostate, with a track record stretching back to the 1980s. Its once-daily dosing and generic availability have kept it in wide use, and clinicians appreciate its dual usefulness in men who have both high blood pressure and prostate-related urinary trouble.

What has genuinely reinvigorated interest in the drug, however, is the discovery of its effect on the energy-producing enzyme PGK1: laboratory and animal work suggests it can raise cellular ATP and protect energy-starved neurons, and several large epidemiological analyses have hinted that men taking terazosin may have a lower risk or slower progression of Parkinson's disease. This has made a decades-old blood-pressure pill an unexpected subject of neurodegeneration research. Honesty requires emphasizing that this neuroprotective potential is still investigational, and that terazosin's alpha-blockade can cause first-dose and orthostatic low blood pressure and dizziness.